This report will excel your competitive awareness and decrease your decision making time in managing breast cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
This report comprises defined and up to date development strategies for 470 breast cancer drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer.
BioSeeker has applied its unique drug assessment methodology to stratify the breast cancer drug pipeline and discern the level of competition in fine detail.Major Findings from this report:
* The identified competitive landscape of breast cancer drugs is split between the approximately one third which have unique drug target strategies and the other two thirds which have head-to-head target competing drugs in 61 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the breast cancer drugs in general.
* Nine out of every ten drug target strategies in Phase II and three out of every four in Phase III development are new to breast cancer drugs.
* The greatest number of new target strategies are found in Phase II (35%) and Preclinical (17%) development.
* Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of breast cancer drugs, which represent almost 80% of the entire pipeline.
* Besides Reformulated drugs, it is Cell therapies, Peptides and Antibodiesbased breast cancer drugs that have the highest cross-over of drug target strategies with other compound strategies.
* The highest number of described drug target strategies of breast cancer drugs belongs to Pfizer, AstraZeneca and Hoffmann-La Roche.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any breast cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.Table of Contents 1 Executive Summary 3
2 About Cancer Highlights™ 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights'™ Five Pillar Drug Assessment 7
4 Table of Contents 94.1 List of Figures 234.2 List of Tables 23
5 Introduction 32
5.1 The Scope of this Report 32
5.2 Definitions 35
5.3 Abbreviations 35
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 366.1 Drug Repositioning in Oncology 366.2 Introduction to Targets of Breast Cancer Drugs 376.2.1 Acid Phosphatase Activity Targets 456.2.2 Auxiliary Transport Protein Activity Targets 466.2.3 Catalytic Activity Targets 476.2.4 Cell Adhesion Molecule Activity Targets 616.2.5 Chaperone Activity Targets 766.2.6 Chemokine Activity Targets 816.2.7 Complement Activity Targets 836.2.8 Cysteine-type Peptidase Activity Targets 866.2.9 Cytokine Activity Targets 946.2.10 DNA Binding Targets 1026.2.11 DNA Repair Protein Targets 1046.2.12 DNA Topoisomerase Activity Targets 1066.2.13 DNA-directed DNA Polymerase Activity Targets 1116.2.14 Extracellular Ligand-gated Ion Channel Activity Targets 1126.2.15 Extracellular Matrix Structural Constituent Targets 1146.2.16 G-protein Coupled Receptor Activity Targets 1156.2.17 Glutathione Transferase Activity Targets 1256.2.18 Growth Factor Activity Targets 1276.2.19 Growth Factor Binding Targets 1346.2.20 Hormone Activity Targets 1356.2.21 Intracellular Ligand-gated Ion Channel Activity Targets 1366.2.22 Ion Channel Activity Targets 1376.2.23 Isomerase Activity Targets 1386.2.24 Kinase Activity Targets 1396.2.25 Kinase Binding Targets 1516.2.26 Kinase Regulator Activity Targets 1526.2.27 Ligand-dependent Nuclear Receptor Activity Targets 1566.2.28 Ligase Activity Targets 1596.2.29 Lipid Kinase Activity Targets 1666.2.30 Lipid Phosphatase Activity Targets 1756.2.31 Metallopeptidase Activity Targets 1766.2.32 Molecular Function Unknown Targets 1806.2.33 Motor Activity Targets 1906.2.34 Oxidoreductase Activity Targets 1926.2.35 Peptidase Activity Targets 2016.2.36 Peptide Hormone Targets 2106.2.37 Peroxidase Activity Targets 2116.2.38 Phosphoric Diester Hydrolase Activity Targets 2126.2.39 Protein Binding Targets 2156.2.40 Protein Serine/Threonine Kinase Activity Targets 2206.2.41 Protein Threonine/Tyrosine Kinase Activity Targets 2586.2.42 Protein-tyrosine Kinase Activity Targets 2636.2.43 Receptor Activity Targets 2746.2.44 Receptor Binding Targets 2916.2.45 Receptor Signaling Complex Scaffold Activity Targets 2996.2.46 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 3036.2.47 RNA Binding Targets 3056.2.48 RNA-directed DNA Polymerase Activity Targets 3066.2.49 Serine-type Peptidase Activity Targets 3076.2.50 Structural Constituent of Cytoskeleton Targets 3106.2.51 Structural Molecule Activity Targets 3136.2.52 Superoxide Dismutase Activity Targets 3156.2.53 T Cell Receptor Activity Targets 3176.2.54 Transcription Factor Activity Targets 3186.2.55 Transcription Regulator Activity Targets 3486.2.56 Transferase Activity Targets 3596.2.57 Translation Regulator Activity Targets 3626.2.58 Transmembrane Receptor Activity Targets 3636.2.59 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 3676.2.60 Transporter Activity Targets 4156.2.61 Voltage-gated Ion Channel Activity Targets 4226.2.62 Other Targets 4236.3 Mutation Profiles of Breast Cancer Drug Targets 4266.3.1 Targets of Breast Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 4266.4 Breast Cancer Therapeutics is Stimulated by Available Structure Data on Targets 4326.5 Target-Target Interactions among Identified Targets of Breast Cancer Drugs 4376.6 The Drug-Target Competitive Landscape 4426.7 Protein Expression Levels of Identified Targets of Breast Cancer Drugs 4476.8 Pathway Assessment of Breast Cancer Drugs 4516.8.1 Tools for Analysis of Cancer Pathways 4526.8.2 Pathway Assessment 453
7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development 523
7.1 Marketed: New and Unique Drug Target Strategies of Breast Cancer Drugs 526
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 528
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 530
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 537
7.5 Preclinical Development: New and Unique Drug Target Strategies of Breast Cancer Drugs 541
7.6 Drug Target Strategies of Suspended or Terminated Breast Cancer Drugs 545
7.7 Target Strategy Development Profiles of Breast Cancer Drugs 549
7.7.1 Marketed 554
7.7.2 Phase III 574
7.7.3 Phase II 583
7.7.4 Phase I 660
7.7.5 Preclinical 695
7.7.6 No Data 734
7.7.7 Suspended 735
7.7.8 Ceased 738
7.8 The Competition Through Close Mechanistic Approximation of Breast Cancer Drugs 786
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy 7988.1 Small Molecules 8008.1.1 Background 8008.1.2 Target Strategies of Small Molecule Drugs 8018.2 Peptide & Protein Drugs 8178.2.1 Background 8178.2.2 Target Strategies of Peptide and Protein Drugs 8188.3 Antibodies 8248.3.1 Background 8248.3.2 Target Strategies of Antibody Drugs 8248.4 Nucleic Acid Therapies 8298.4.1 Background 8298.4.2 Target Strategies of Nucleic Acid Drugs 8308.5 Cell & Gene Therapy 8328.5.1 Background 8328.5.2 Target Strategies of Cell and Gene Therapy Drugs 8338.6 Drug Delivery and Nanotechnology 8388.6.1 Background 8388.6.2 Target Strategies of Reformulated Drugs 8388.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 842